NCT03228277View on ClinicalTrials.gov

Olmutinib Trial in T790M (+) NSCLC Patients Detected by Liquid Biopsy Using BALF Extracellular Vesicular DNA

PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

July 17, 2017

Primary Completion Date

July 31, 2018

Study Completion Date

July 31, 2019

Conditions
Non Small Cell Lung Cancer
Interventions
DRUG

Olmutinib

Patients to be provided with Olmutinib 800mg (2 x 400 mg tablets) once daily (QD)

Trial Locations (1)

05030

Konkuk University Medical Center, Seoul

Sponsors
All Listed Sponsors
collaborator

Hanmi Pharmaceutical Company Limited

INDUSTRY

lead

Konkuk University Medical Center

OTHER

NCT03228277 - Olmutinib Trial in T790M (+) NSCLC Patients Detected by Liquid Biopsy Using BALF Extracellular Vesicular DNA | Biotech Hunter | Biotech Hunter